BRPI0906436A2 - Derivados de ftalazinona - Google Patents
Derivados de ftalazinonaInfo
- Publication number
- BRPI0906436A2 BRPI0906436A2 BRPI0906436-2A BRPI0906436A BRPI0906436A2 BR PI0906436 A2 BRPI0906436 A2 BR PI0906436A2 BR PI0906436 A BRPI0906436 A BR PI0906436A BR PI0906436 A2 BRPI0906436 A2 BR PI0906436A2
- Authority
- BR
- Brazil
- Prior art keywords
- phthalazinone derivatives
- phthalazinone
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2290008P | 2008-01-23 | 2008-01-23 | |
US14241309P | 2009-01-05 | 2009-01-05 | |
PCT/GB2009/000181 WO2009093032A1 (en) | 2008-01-23 | 2009-01-23 | Phthalazinone derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0906436A2 true BRPI0906436A2 (pt) | 2015-07-14 |
Family
ID=40510546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0906436-2A BRPI0906436A2 (pt) | 2008-01-23 | 2009-01-23 | Derivados de ftalazinona |
Country Status (24)
Country | Link |
---|---|
US (2) | US8129380B2 (pt) |
EP (1) | EP2231638A1 (pt) |
JP (1) | JP2011510056A (pt) |
KR (1) | KR20100116187A (pt) |
CN (1) | CN101925595A (pt) |
AR (1) | AR070221A1 (pt) |
AU (1) | AU2009207498A1 (pt) |
BR (1) | BRPI0906436A2 (pt) |
CA (1) | CA2708175A1 (pt) |
CL (1) | CL2009000133A1 (pt) |
CO (1) | CO6290715A2 (pt) |
DO (1) | DOP2010000219A (pt) |
EA (1) | EA201070523A1 (pt) |
EC (1) | ECSP10010349A (pt) |
IL (1) | IL206026A0 (pt) |
MX (1) | MX2010006364A (pt) |
NI (1) | NI201000120A (pt) |
NZ (1) | NZ585982A (pt) |
PE (1) | PE20091335A1 (pt) |
SV (1) | SV2010003625A (pt) |
TW (1) | TW200936577A (pt) |
UY (1) | UY31603A1 (pt) |
WO (1) | WO2009093032A1 (pt) |
ZA (1) | ZA201003752B (pt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006115221A1 (ja) * | 2005-04-21 | 2006-11-02 | Nippon Shinyaku Co., Ltd. | フタラジノン誘導体及びその医薬 |
GB0521373D0 (en) * | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
CA2637388C (en) * | 2006-01-16 | 2013-12-17 | Ube Industries, Ltd. | Pyrrolopyridazinone compound |
US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
TW200900396A (en) * | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
WO2011007145A1 (en) | 2009-07-15 | 2011-01-20 | Astrazeneca Ab | Phthalazinone compound as parp inhibitor |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
US9051296B2 (en) | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
WO2012014221A1 (en) | 2010-07-27 | 2012-02-02 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors |
CN102372706A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
CN102485721B (zh) * | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
EP3925962A1 (en) | 2011-05-31 | 2021-12-22 | Rakovina Therapeutics Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerase |
AR088352A1 (es) * | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
CN103130723B (zh) * | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
CN102702108A (zh) * | 2012-06-27 | 2012-10-03 | 上海大学 | 1,2-二氢酞嗪类化合物及其合成方法 |
CN102863393A (zh) * | 2012-09-26 | 2013-01-09 | 上海大学 | 1,2-二氢酞嗪类化合物及其合成方法 |
WO2014085208A1 (en) * | 2012-11-27 | 2014-06-05 | Merck Sharp & Dohme Corp. | 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists |
JP5930452B2 (ja) | 2012-12-31 | 2016-06-08 | カディラ・ヘルスケア・リミテッド | 置換フタラジン‐1(2h)‐オン誘導体 |
EP2964226A4 (en) * | 2013-03-08 | 2016-08-10 | Merck Sharp & Dohme | 2-pyridyloxy-4-ESTER-orexin receptor antagonists |
SG11201600743WA (en) * | 2013-07-31 | 2016-02-26 | Merck Patent Gmbh | Oxoquinazolinyl-butanamide derivatives |
KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
CN109415345B (zh) * | 2016-06-29 | 2022-01-11 | 豪夫迈·罗氏有限公司 | 基于哒嗪酮的广谱抗流感抑制剂 |
RS60209B1 (sr) | 2017-03-20 | 2020-06-30 | Forma Therapeutics Inc | Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr) |
EP3615026B1 (en) | 2017-04-28 | 2021-03-03 | Akribes Biomedical GmbH | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
WO2019169156A1 (en) * | 2018-02-28 | 2019-09-06 | The Trustees Of The University Of Pennsylvania | Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents |
CN110577953B (zh) * | 2018-06-11 | 2024-02-20 | 深圳华大生命科学研究院 | 基因突变体及其应用 |
CN108727338B (zh) * | 2018-07-05 | 2020-12-15 | 福建医科大学 | 一种4-哌啶酮类化合物及其制备方法与应用 |
US11001588B2 (en) | 2018-09-19 | 2021-05-11 | Forma Therapeutics, Inc. | Activating pyruvate kinase R and mutants thereof |
US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
CN109748923A (zh) * | 2019-01-31 | 2019-05-14 | 中国药科大学 | 含苯并[4,5]咪唑[1,2-a]吡嗪酮类衍生物及其制备方法与用途 |
CN113811333B (zh) * | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
CR20220070A (es) | 2019-07-19 | 2022-03-21 | Astrazeneca Ab | Inhibidores de parp1 |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
MX2022013304A (es) | 2020-04-21 | 2022-12-15 | Idience Co Ltd | Formas cristalinas de compuesto de ftalazinona. |
CN115720580A (zh) | 2020-04-21 | 2023-02-28 | 伊迪恩斯股份有限公司 | 用于制备酞嗪酮衍生物和其中间体的方法 |
US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
CN112624981B (zh) * | 2021-03-09 | 2021-05-25 | 南京桦冠生物技术有限公司 | 一种2-氟-5-[(4-氧代-3h-2,3-二氮杂萘基)甲基]苯甲酸的制备方法 |
IL306010A (en) | 2021-03-23 | 2023-11-01 | Nuvation Bio Inc | Anticancer compounds against the nuclear hormone receptor |
AU2022251588A1 (en) | 2021-04-01 | 2023-10-19 | Transthera Sciences (Nanjing) , Inc. | Method for preparing phosphodiesterase inhibitor |
AU2022269568A1 (en) | 2021-05-03 | 2023-11-16 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
EP4387966A1 (en) * | 2021-08-17 | 2024-06-26 | InventisBio Co., Ltd. | Pyridazinone or pyridinone compounds, preparation methods and uses thereof |
WO2024146631A1 (zh) * | 2023-01-06 | 2024-07-11 | 齐鲁制药有限公司 | 一种parp7抑制剂的制备方法 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB721286A (en) | 1951-02-16 | 1955-01-05 | Smith Kline & French Internat | Improvements in or relating to the preparation of tetrahydroisoquinolone derivatives |
DE2143745A1 (de) | 1971-09-01 | 1973-03-08 | Hoechst Ag | 3,4-dihydro-2h-isochinolin-1-thione und verfahren zu ihrer herstellung |
US3813384A (en) | 1972-01-17 | 1974-05-28 | Asta Werke Ag Chem Fab | Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof |
FR2262513A1 (en) | 1974-03-01 | 1975-09-26 | Delalande Sa | 3,4,5-Triphenyl-delta-1,2,4-oxadiazolines - with bronchodilator, anti-cholinergic, hypertensive, analgesic and sedative activity |
JPS54156526A (en) | 1978-05-31 | 1979-12-10 | Asahi Chemical Ind | Dry picture forming material |
US4283539A (en) | 1979-12-18 | 1981-08-11 | Pfizer Inc. | Isoquinoline acetic acids |
JPS58164577A (ja) | 1982-03-24 | 1983-09-29 | Taiho Yakuhin Kogyo Kk | 4―ベンジル―1―(2h)イソキノロン誘導体 |
US4665181A (en) | 1984-05-17 | 1987-05-12 | Pennwalt Corporation | Anti-inflammatory phthalazinones |
US5041653A (en) | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
US5032617A (en) | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
US5215738A (en) | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
ATE60598T1 (de) | 1985-11-11 | 1991-02-15 | Asta Pharma Ag | 4-benzyl-1-(2h)-phthalazinon-derivate. |
GB8610018D0 (en) | 1986-04-24 | 1986-05-29 | Fujisawa Pharmaceutical Co | Phthalazine derivatives |
DE3640641A1 (de) | 1986-11-28 | 1988-07-14 | Thomae Gmbh Dr K | Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE3813531A1 (de) | 1987-05-02 | 1988-11-10 | Asta Pharma Ag | Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate |
ATE117553T1 (de) | 1988-08-19 | 1995-02-15 | Warner Lambert Co | Substituierte dihydroisochinolinone und verwandte verbindungen als verstärker der letalen effekte von bestrahlung und bestimmten chemotherapeutika; ausgewählte verbindungen, analoga und verfahren. |
DK0389995T3 (da) | 1989-03-28 | 1995-07-03 | Nisshin Flour Milling Co | Isoquinolinderivater til behandling af glaukom eller okular hypertension |
DD287032A5 (de) | 1989-07-28 | 1991-02-14 | Karl-Marx-Universitaet Leipzig,De | Verfahren zur herstellung von 3-carbamoyl-4-aryl-1,2-di-hydro-isochinolin-1h-onen |
GB9011833D0 (en) | 1990-05-25 | 1990-07-18 | Collins Mary K L | Inhibition of viral infection |
EP0502575A1 (en) | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
AU3440693A (en) | 1992-01-17 | 1993-08-03 | Syntex (U.S.A.) Inc. | Substituted 1-isoquinolone derivatives as angiotensin II antagonists |
CZ199593A3 (en) | 1992-10-02 | 1994-04-13 | Asta Medica Ag | Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr) |
AU5455194A (en) | 1992-11-02 | 1994-05-24 | Merck & Co., Inc. | Substituted phthalazinones as nerotensin antagonists |
EP0634404A1 (en) | 1993-07-13 | 1995-01-18 | Rhone Poulenc Agriculture Ltd. | Phtalazin derivatives and their use as pesticides |
US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
US5648355A (en) | 1994-02-09 | 1997-07-15 | Kos Pharmaceutical, Inc. | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
ES2164136T5 (es) | 1994-08-12 | 2009-02-16 | The University Of Utah Research Foundation | Sondas de acidos nucleicos que copmrenden un fragmento del gen de susceptibilidad al cancer de mama y ovarios asociado a 17q. |
MX9701075A (es) | 1994-08-12 | 1998-03-31 | Myriad Genetics Inc | Mutaciones en vivo y polimorfismos en el gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q. |
US5589483A (en) | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
US5834466A (en) | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
IL120264A0 (en) | 1996-02-29 | 1997-06-10 | Pfizer | Method of reducing tissue damage associated with non-cardiac ischemia |
CN1136197C (zh) | 1996-05-30 | 2004-01-28 | 霍夫曼-拉罗奇有限公司 | 新的哒嗪酮衍生物 |
US5888529A (en) | 1997-03-28 | 1999-03-30 | The Regents Of The University Of California | Ileus treatment method |
IL132758A0 (en) | 1997-05-13 | 2001-03-19 | Octamer Inc | Methods for treating inflammation and inflammatory diseases using padprt |
WO1999008680A1 (en) | 1997-08-15 | 1999-02-25 | The Johns Hopkins University | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
US6426415B1 (en) | 1997-09-03 | 2002-07-30 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity |
US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
WO1999025340A1 (en) | 1997-11-14 | 1999-05-27 | Eli Lilly And Company | Treatment for alzheimer's disease |
JP2002505288A (ja) | 1998-03-02 | 2002-02-19 | コセンシス,インコーポレイテッド | 置換キナゾリンおよびアナログならびにそれらの使用 |
FR2776291B1 (fr) | 1998-03-18 | 2000-06-16 | Pf Medicament | Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament |
ITMI981671A1 (it) | 1998-07-21 | 2000-01-21 | Zambon Spa | Derivati ftalazinici inibitori della fosfodisterasi 4 |
US6495541B1 (en) | 1999-01-11 | 2002-12-17 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
WO2000044726A1 (fr) | 1999-01-26 | 2000-08-03 | Ono Pharmaceutical Co., Ltd. | Derives 2h-phthalazine-1-one et medicaments renfermant ces derives comme principe actif |
DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
US6465448B1 (en) | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
WO2001021615A1 (en) | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
WO2001023390A2 (de) | 1999-09-28 | 2001-04-05 | Basf Aktiengesellschaft | Azepinoindol-derivate, deren herstellung und anwendung |
US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
ATE372337T1 (de) | 2000-02-01 | 2007-09-15 | Abbott Gmbh & Co Kg | Heterozyklische verbindungen und deren anwendung als parp-inhibitoren |
WO2001079184A1 (fr) | 2000-04-18 | 2001-10-25 | Sumitomo Pharmaceuticals Company, Limited | Composes de piperazine substitues |
US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
DE10022925A1 (de) | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
WO2001087845A2 (en) | 2000-05-15 | 2001-11-22 | Fujisawa Pharmaceutical Co., Ltd. | N-containing heterocyclic compounds and their use as 5-ht antagonists |
US6723733B2 (en) | 2000-05-19 | 2004-04-20 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
KR100804564B1 (ko) | 2000-10-30 | 2008-02-20 | 쿠도스 파마슈티칼스 리미티드 | 프탈라지논 유도체 |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
AU2002220241A1 (en) | 2000-12-01 | 2002-06-11 | Iconix Pharmaceuticals, Inc. | Parb inhibitors |
WO2002068407A1 (fr) | 2001-02-28 | 2002-09-06 | Yamanouchi Pharmaceutical Co., Ltd. | Compose benzimidazole |
EP1397350B1 (en) | 2001-05-08 | 2007-02-28 | Kudos Pharmaceuticals Limited | Isoquinolinone derivatives as parp inhibitors |
JPWO2002094790A1 (ja) | 2001-05-23 | 2004-09-09 | 三菱ウェルファーマ株式会社 | 縮合ヘテロ環化合物およびその医薬用途 |
WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
AU2002358650A1 (en) | 2001-12-14 | 2003-06-30 | Altana Pharma Ag | Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors |
AUPR975601A0 (en) | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
US7157452B2 (en) | 2001-12-31 | 2007-01-02 | Mgi Gp, Inc. | Substituted 4,9-dihydrocyclopenta{imn}phenanthridine-5-ones derivatives thereof and their uses |
AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
BR0307780A (pt) | 2002-02-19 | 2004-12-28 | Ono Pharmaceutical Co | Compostos derivados de piridazina fundida e medicamentos contendo os compostos como o ingrediente ativo |
US7196085B2 (en) | 2002-04-30 | 2007-03-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
KR101146806B1 (ko) * | 2003-03-12 | 2012-05-22 | 메이브릿지 리미티드 | 프탈라지논 유도체 |
DK1684736T3 (da) | 2003-12-01 | 2011-11-21 | Kudos Pharm Ltd | Inhibitorer af DNA-skadereparation til behandling af cancer |
MX2007002318A (es) * | 2004-08-26 | 2007-04-17 | Kudos Pharm Ltd | Derivados de ftalazinona substituidos con 4-heteroarilmetilo. |
GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
EP1908481A1 (en) | 2005-06-24 | 2008-04-09 | Ono Pharmaceutical Co., Ltd. | Agent for reduction of bleeding in cerebrovascular disorder |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
EP2032140A1 (en) * | 2006-05-31 | 2009-03-11 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
MX347085B (es) | 2006-12-28 | 2017-04-06 | Abbott Laboratories * | Inhibidores de la poli (adp-ribosa) polimerasa. |
US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
US20090023727A1 (en) | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
RU2010108008A (ru) * | 2007-09-14 | 2011-10-20 | Астразенека Аб (Se) | Фталазиноновые производные |
-
2009
- 2009-01-21 AR ARP090100183A patent/AR070221A1/es not_active Application Discontinuation
- 2009-01-21 UY UY031603A patent/UY31603A1/es not_active Application Discontinuation
- 2009-01-22 US US12/357,957 patent/US8129380B2/en not_active Expired - Fee Related
- 2009-01-23 BR BRPI0906436-2A patent/BRPI0906436A2/pt not_active IP Right Cessation
- 2009-01-23 CN CN2009801027174A patent/CN101925595A/zh active Pending
- 2009-01-23 EA EA201070523A patent/EA201070523A1/ru unknown
- 2009-01-23 PE PE2009000100A patent/PE20091335A1/es not_active Application Discontinuation
- 2009-01-23 KR KR1020107017727A patent/KR20100116187A/ko not_active Application Discontinuation
- 2009-01-23 EP EP09703506A patent/EP2231638A1/en not_active Withdrawn
- 2009-01-23 CA CA2708175A patent/CA2708175A1/en not_active Abandoned
- 2009-01-23 JP JP2010543563A patent/JP2011510056A/ja active Pending
- 2009-01-23 WO PCT/GB2009/000181 patent/WO2009093032A1/en active Application Filing
- 2009-01-23 TW TW098103128A patent/TW200936577A/zh unknown
- 2009-01-23 MX MX2010006364A patent/MX2010006364A/es not_active Application Discontinuation
- 2009-01-23 AU AU2009207498A patent/AU2009207498A1/en not_active Abandoned
- 2009-01-23 NZ NZ585982A patent/NZ585982A/en not_active IP Right Cessation
- 2009-01-23 CL CL2009000133A patent/CL2009000133A1/es unknown
-
2010
- 2010-05-26 ZA ZA2010/03752A patent/ZA201003752B/en unknown
- 2010-05-27 IL IL206026A patent/IL206026A0/en unknown
- 2010-07-16 DO DO2010000219A patent/DOP2010000219A/es unknown
- 2010-07-16 EC EC2010010349A patent/ECSP10010349A/es unknown
- 2010-07-16 CO CO10087223A patent/CO6290715A2/es not_active Application Discontinuation
- 2010-07-16 NI NI201000120A patent/NI201000120A/es unknown
- 2010-07-19 SV SV2010003625A patent/SV2010003625A/es not_active Application Discontinuation
-
2012
- 2012-01-30 US US13/361,911 patent/US20120129855A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NZ585982A (en) | 2011-12-22 |
CA2708175A1 (en) | 2009-07-30 |
ECSP10010349A (es) | 2010-08-31 |
JP2011510056A (ja) | 2011-03-31 |
NI201000120A (es) | 2011-03-23 |
UY31603A1 (es) | 2009-08-31 |
ZA201003752B (en) | 2011-03-30 |
KR20100116187A (ko) | 2010-10-29 |
US8129380B2 (en) | 2012-03-06 |
WO2009093032A1 (en) | 2009-07-30 |
CN101925595A (zh) | 2010-12-22 |
EP2231638A1 (en) | 2010-09-29 |
MX2010006364A (es) | 2010-07-05 |
US20120129855A1 (en) | 2012-05-24 |
PE20091335A1 (es) | 2009-10-04 |
CL2009000133A1 (es) | 2010-10-15 |
US20090192156A1 (en) | 2009-07-30 |
SV2010003625A (es) | 2011-05-20 |
CO6290715A2 (es) | 2011-06-20 |
EA201070523A1 (ru) | 2011-02-28 |
DOP2010000219A (es) | 2010-08-15 |
IL206026A0 (en) | 2010-11-30 |
AU2009207498A1 (en) | 2009-07-30 |
AR070221A1 (es) | 2010-03-25 |
TW200936577A (en) | 2009-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0906436A2 (pt) | Derivados de ftalazinona | |
DK2308877T3 (da) | Imidazopyridin-2-on-derivater | |
BRPI0813707A2 (pt) | Derivados de pirimidinil-piridazinona | |
BRPI0820112A2 (pt) | Derivados de isoxazol-piridina | |
BRPI0809992A2 (pt) | Derivados de pirrolopirimidina | |
BRPI0820113A2 (pt) | Derivados de isoxazolo-piridazina | |
BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
DK2209786T3 (da) | Pyrimidinsubstituerede purinderivater | |
BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
BRPI0923497A2 (pt) | derivados de piridazinona | |
BRPI0817935A2 (pt) | Derivados de biarila | |
BRPI0812155A2 (pt) | derivados de espiroindolinona | |
BRPI0907435A2 (pt) | Derivados de 5-flúor pirimidina | |
BRPI0813836A2 (pt) | Derivados pirazólicos | |
BRPI0812518A2 (pt) | Derivados de indazolamida | |
BRPI0814236A2 (pt) | Derivados de quinazolinamida | |
BRPI0914544A2 (pt) | derivados de pirimidona substituídos | |
BRPI0820649A2 (pt) | Derivados de isoxazalo-pirazina | |
BRPI0812247A2 (pt) | Derivados de piridazinona | |
DK2275414T3 (da) | Cyclopentylacrylamidderivat | |
DK2152370T3 (da) | Aryletherpyridazinonderivater | |
DK2318378T3 (da) | Quinazolin-derivater | |
BRPI0920496A2 (pt) | derivados substituídos de pirimidina etriazina | |
ATE545635T1 (de) | Substituierte n-oxidpyrazinderivate | |
BRPI0913234A2 (pt) | derivados de tiazolilpiperidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |